- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
DOACS Effectively Reduces VTE Recurrence in Cancer Patients
Direct oral anticoagulants (DOACs) are now considered the standard of care for the treatment of venous thromboembolism (VTE) in noncancer patients for several reasons. A recent study suggests that DOACs should be included in the standard of care to prevent VTE recurrence in adult cancer patients except for those with a high risk of bleeding. The study findings were published in the Mayo Clinic Proceedings on June 22, 2021.
Thrombotic outcomes increase mortality in cancer patients and are the second most common cause of death after disease progression. The data relating to DOACs for the treatment of cancer-associated thrombosis (CAT) are rapidly emerging and have challenged low-molecular-weight heparin (LMWH) as the preferred option. To further explore, researchers of Mayo Clinic conducted a study to assess the benefits and harms of different treatment options in adults with CAT using artificial intelligence (AI) technology.
In this systemic review and meta-analysis, the researchers developed an AI called LIvE synthesis framework to maintain a living, interactive systematic review since September 19, 2018. It will constantly update the results as new information becomes available. Using AI, they continually searched the literature to find a new study. Once filtering required studies, then with the guidance of experts in the field, they made some updates to their dataset. For this study, they included four randomized controlled trials (Caravaggio, ADAM VTE, SELECT D, and Hokusai VTE) and examined the data of 2,894 patients with either active cancer or a history of cancer.
Key findings of the study:
- Upon analysis, the researchers found that the DOACs significantly decrease recurrent VTE events compared with dalteparin (odds ratio [OR], 0.59) without significantly increasing major bleeding (OR, 1.34).
- In mixed treatment comparisons, they found that apixaban (OR, 0.41) and rivaroxaban (OR, 0.58) significantly decrease VTE recurrent events compared with dalteparin.
- However, they noted that edoxaban significantly increases major bleeding compared with dalteparin (OR, 1.73), and rivaroxaban significantly increases clinically relevant nonmajor bleeding compared with dalteparin and other DOACs.
- They also noted no significant differences between DOACs in terms of VTE recurrences and major bleeding.
The authors concluded, "DOACs should be considered a standard of care for the treatment of CAT except in patients with a high risk of bleeding. Current evidence favours the use of apixaban for the treatment of CAT among other DOACs."
For further information:
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751